@article{f0a213b4ea9e48fa81e54e4d189ee2d9,
title = "Balancing access to BPaLM regimens and risk of resistance",
keywords = "Mycobacterium tuberculosis, Multidrug resistance (MDR), Antimycobacterial agents, BPaLM regimens, risk of resistance",
author = "{Van Rie}, Annelies and Timothy Walker and {de Jong}, Bouke and Praharshinie Rupasinghe and Emmanuel Rivi{\`e}re and V{\'e}ronique Dartois and Lindsay Sonnenkalb and Diana Machado and S{\'e}bastien Gagneux and Philip Supply and Viola Dreyer and Stefan Niemann and Galo Goig and Conor Meehan and Elisa Tagliani and Cirillo, {Daniela Maria}",
note = "Funding Information: AVR reports receiving funding from Research Foundation Flanders (Belgium) related to whole-genome sequencing of M tuberculosis. BdJ reports an institutional contract for central laboratory support to the C211 pediatric bedaquiline trial with Janssen and participation in the scientific advisory boards of the Dioraphte foundation and Panacea. PS reports personal consulting fees from Genoscreen. DMC reports receiving grants from European Committee on Antimicrobial Susceptibility Testing (EUCAST) to study epidemiological cut-off values (ECOFFs) in EUCAST-recommenced methods, funding from UNITE4TB to study ECOFF distributions of drugs included in clinical trials, and participating in the TB alliance study on the M tuberculosis lineage 1 distribution. All other authors declare no competing interests.",
year = "2022",
month = oct,
doi = "10.1016/S1473-3099(22)00543-6",
language = "English",
volume = "22",
pages = "1411--1412",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Elsevier Science B.V., Amsterdam.",
number = "10",
}
